Gerry Smith on Muck Rack

Gerry Smith

Verified
New York
As seen in: Bloomberg News, UOL Economia, CNN, Medium, MSN, MSN Singapore, UOL, Bloomberg Businessweek, Bloomberg Green Daily, Bloomberg Markets Magazine, Estadão and
Covers:  hackers, telecom, cybersecurity
Biotech reporter for @business. Views are my own. Tips: gsmith233@bloomberg.net

Get in touch with Gerry

Contact Gerry, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Gerry Smith’s Biography

Read Full Bio →

Technology Reporter, The Huffington Post

Gerry Smith’s Journalist Portfolio

How The iPhone Became An Object Worth Killing For

How The iPhone Became An Object Worth Killing For

When Sunah Yang bought an iPhone for her brother two years ago, she warned him about the white earbuds. Never…

View article →

Articles

Chinese pharma contractor under watch: Pentagon names WuXi AppTec on military list

|
By Gerry Smith Verified, Amber Tong Verified
| ThePrint Verified
Any restriction that stems from the designation could have broader implications because WuXi AppTec helps conduct research and development efforts on behalf of many US drugmakers. That includes a disproportionate impact on small- and mid-cap biotech companies that tend to rely on low-cost, high-quality Chinese service providers, Humphrey wrote in a note.
Open in Who Shared View Duplicates (9) Issue with article?

五角大樓將中資生物科技巨頭藥明康德列入中國軍方企業名單

|
By Gerry Smith Verified
| Yahoo! Finance Hong Kong Verified
【彭博】-- 五角大樓將藥明康德列入與中國軍方有關聯的企業名單，此舉可能威脅這家中資醫藥研發外包巨頭的業務，並可能令美國製藥商正在開展的研發工作更趨複雜。 藥明康德為全球多家大型製藥公司提供包括藥物發現在內的多種服務。彭博此前報導稱，截至2024年，禮來公司的減肥藥Zepbound所使用的活性基礎成分中，很大一部分由藥明康德生產。 美國國防部的這項認定，是美中圍繞藥物研發和生產緊張關係加劇的最新信號。諮詢公司Capstone醫療健保團隊副總裁Will Humphrey表示，這可能危及藥明康德的一項主要收入來源。該公司去年約四分之三的銷售額來自美國業務。 去年12月通過的《生物安全法》規定，美國政府機構不得與接受美國國防部「中國軍方企業」清單內公司服務的任何組織簽約。 藥明康德表示，被列入這份清單「顯然是個錯誤」。該公司發言人在發給彭博新聞社的電子郵件聲明中表示，「我們並不符合被認定為‘中國軍方企業’的法定標準」，藥明康德不受任何中國軍方或政府實體的控制。 藥明系的另一家公司藥明生物未被五角大樓列入與中國軍方有關聯的企業名單。 原文標題Pentagon Names Biotech...
Open in Who Shared Issue with article?

Incyte to Buy Blood Disorder Biotech for Up to $2 Billion (1) Original

|
By Gerry Smith Verified
| Bloomberg Law Verified
agreed to buy Vega Therapeutics Inc. for as much as $2 billion to gain potential new treatments for bleeding disorders. Under the deal, Incyte will pay Vega’s parent, the closely held , $1.25 billion upfront and as much as $750 million in additional payments for achieving certain milestones, according to a statement Monday. The acquisition bolsters Incyte’s product pipeline as its top drug, the blood cancer treatment Jakafi, faces patent expiration in a few years, eroding its revenue.
Open in Who Shared View Duplicates (2) Issue with article?
See all 3,922 licensed articles (6,271 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified